

# Neuroprotective and anti-inflammatory effects of eicosane on glutamate and NMDA-induced retinal ganglion cell injury

Zhen-Kai Wu<sup>1,2</sup>, Huan-Yu Li<sup>2</sup>, You-Lin Zhu<sup>2</sup>, Meng-Qin Xiong<sup>2</sup>, Jing-Xiang Zhong<sup>1</sup>

<sup>1</sup>Department of Ophthalmology, the First Affiliated Hospital of Jinan University, Guangzhou 510632, Guangdong Province, China

<sup>2</sup>Changde Hospital, Xiangya School of Medicine, Central South University (the First People's Hospital of Changde City), Changde 415000, Hunan Province, China

**Correspondence to:** Jing-Xiang Zhong. Department of Ophthalmology, the First Affiliated Hospital of Jinan University, Guangzhou 510632, Guangdong Province, China. zjx85221206@163.com

Received: 2023-12-08 Accepted: 2024-01-18

## Abstract

• **AIM:** To investigate the protective effects, antioxidant potential, and anti-inflammatory mechanisms of eicosane on glutamate-induced cell damage and on N-methyl-D-aspartate (NMDA)-induced retinal ganglion cell (RGC) injury in a mouse model of glaucoma.

• **METHODS:** The protective effects of eicosane on the rat R28 retinal precursor cell line were assessed using cell counting kit-8 assays and Hoechst-propidium iodide staining. Intracellular reactive oxygen species (ROS) production was measured using the fluorescent probe 2'-7'-dichlorofluorescein diacetate and flow cytometry. The protective role of eicosane on NMDA-induced RGC injury in a mouse glaucoma model was determined by immunostaining of frozen sections of retina. The effects of eicosane on the metabolome of the retina in mice with NMDA-induced RGC damage were evaluated by liquid chromatography-mass spectroscopy (LC-MS) and untargeted metabolomics analyses.

• **RESULTS:** Eicosane treatment significantly attenuated glutamate-induced damage to R28 cells *in vitro*. Eicosane also protected RGCs against NMDA-induced injury in a mouse glaucoma model. Untargeted metabolomics analyses showed that eicosane increased multiple metabolites, including L-arginine and L-carnitine, in the retina.

• **CONCLUSION:** Eicosane has protective effects, antioxidant potential, and anti-inflammatory properties

in an *in vitro* model of glutamate-induced cell damage and in an *in vivo* model of NMDA-induced RGC injury in mouse glaucoma through modulation of L-arginine and/or L-carnitine metabolism.

• **KEYWORDS:** glaucoma; metabolites; eicosane

**DOI:10.18240/ijo.2024.04.05**

**Citation:** Wu ZK, Li HY, Zhu YL, Xiong MQ, Zhong JX. Neuroprotective and anti-inflammatory effects of eicosane on glutamate and NMDA-induced retinal ganglion cell injury. *Int J Ophthalmol* 2024;17(4):638-645

## INTRODUCTION

Glaucoma, a disease characterized by the progressive loss of retinal ganglion cells (RGCs) and subsequent visual impairment, is a major cause of blindness worldwide. The pathogenesis of glaucoma is thought to involve oxidative stress and inflammation, which contribute significantly to RGC death. Plant extracts may protect against oxidative stress and inflammation in glaucoma, with many plant extracts demonstrating neuroprotective effects in animal models of glaucoma and other neurodegenerative diseases. These neuroprotective effects are thought to involve several mechanisms of action, including the reduction of oxidative stress, the inhibition of inflammation, and the promotion of cell survival<sup>[1-4]</sup>.

The potential neuroprotective effects of specific active ingredients derived from plant extracts have been analyzed. For example, the neuroprotective properties of grape seed extract have been tested in various neurological conditions, including Alzheimer's disease and stroke. The active components of grape seed extract, particularly flavonoids, have exhibited antioxidant and anti-inflammatory properties<sup>[5-6]</sup>. Despite these advances, comprehensive analysis of all plant extract-derived ingredients with proven neuroprotective properties and their associated mechanisms remains challenging. The complexity of these interactions underscores the research required to determine the full spectrum of neuroprotective properties inherent in plant extracts.

A previous study showed that ethanol extracts of *Echium amoenum* L. (*E. amoenum* L.) have robust neuroprotective efficacy in models of glutamate-induced and optic nerve crush (ONC)-induced cell death. These effects were thought to be due to the inherent antioxidant and anti-inflammatory properties of these plant extracts. A comprehensive analysis of an ethanol extract of *E. amoenum* L., using gas chromatography-mass spectrometry (GC-MS), showed the presence of various compounds, including palmitic acid, hexadecanoic acid, octadecadienoic acid, docosane, campesterol, tetracosane, linolenic acid, eicosane, docosane, and nonacosane<sup>[7]</sup>. However, the specific compound(s) responsible for mediating the neuroprotective effect of this extract remain unclear. Identifying these neuroprotective compounds is necessary for a comprehensive understanding of the therapeutic potential inherent in the ethanol extract of *E. amoenum* L.

N-methyl-D-aspartate (NMDA) receptors are expressed on RGCs and play a pivotal role in the physiological function of these cells. Under pathological conditions such as glaucoma, however, these receptors may undergo overactivation, precipitating excitotoxicity and consequent damage to RGCs. The current study was designed to evaluate the potential neuroprotective effects of individual components derived from *E. amoenum* L. extract. The underlying mechanisms of action of these compounds were assessed using an *in vitro* model of glutamate-induced cell damage and an *in vivo* model of NMDA-induced RGC injury in mouse glaucoma. Eicosane was found to significantly attenuate glutamate-induced damage to R28 cells *in vitro* and to protect RGCs against NMDA-induced injury in a mouse glaucoma model *in vivo*. The neuroprotective effects of eicosane were likely due to its inherent antioxidant and anti-inflammatory properties. These findings may provide clues to a potential treatment for mitigating glutamate-induced cellular damage and RGC injury in patients with glaucoma.

Alterations in the comprehensive metabolite profile of an organism under specific conditions can be assessed by metabolomics using liquid chromatography mass spectrometry (LC-MS) technology. This analytical method can facilitate investigation of overall biological function and changes in endogenous substances, including within the retinal microenvironment. Despite the pivotal role of RGCs in glaucoma pathology, few studies have explored the metabolic regulatory mechanisms within the retinal microenvironment in mouse glaucoma models. Analyzing the effects of neuroprotective agents on metabolic regulatory pathways in RGCs may provide insight into potential targets for RGC neuroprotection. The present study therefore included untargeted metabolomics analyses to investigate eicosane-associated changes in the metabolome of the retina in mice with NMDA-induced RGC

damage. Eicosane treatment was found to induce increases in several metabolites, notably L-arginine and L-carnitine. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis demonstrated that eicosane treatment modulated various metabolic pathways, including autophagy, the mTOR pathway, and the L-arginine metabolic pathway. These findings substantiate the protective effects of eicosane on RGC damage in glaucoma, effects likely due to the antioxidative stress properties of eicosane, its regulation of L-arginine and L-carnitine metabolism, and its modulation of autophagy and mTOR pathways. This study evaluated the potential neuroprotective properties of eicosane, a single compound derived from *E. amoenum* L. extract, on RGCs in glaucoma models at the cellular and molecular levels, and provided clues to the treatment of patients with glaucoma. Taken together, these findings may contribute to elucidating the neuroprotective mechanism of eicosane, thereby establishing a foundation for subsequent clinical intervention.

## MATERIALS AND METHODS

**Ethical Approval** All animal experiments were conducted in accordance with the Animal Ethics Guidelines of Xiangya Hospital, Central South University (permit number: 202108022).

**Animals** Mice fed a normal diet were orally administered 20 mg/kg eicosane once daily for 10d. Subsequently, 1  $\mu$ L 50 mmol/L NMDA was injected into the vitreous cavity of both eyes using a 33-gauge needle. Control mice were fed a normal diet and were intravitreally injected with the same volume of phosphate buffered saline (PBS).

**Cell Viability, Cell Death Assays and Reactive Oxygen Species Production** The individual constituents of *E. amoenum* L. extract, including palmitic acid, hexadecanoic acid, octadecadienoic acid, docosane, campesterol, tetracosane, linolenic acid, docosane, eicosane and nonacosane, were obtained from Targetmol (Boston, MA, USA). R28 cells were treated with 10  $\mu$ mol/L of each compound and 10 mmol/L glutamate for 12h, and cell viability, cell death and reactive oxygen species (ROS) production were assayed as described previously<sup>[7]</sup>. Briefly, cell viability was determined using Cell Counting Kit-8 (CCK-8; Servicebio, China) assays, and cell death was determined using Apoptosis and Necrosis Assay Kits (Beyotime, Shanghai, China), according to the manufacturers' instructions. ROS production was determined using the fluorescent probe 2',7'-dichlorofluorescein diacetate (Sigma-Aldrich, St. Louis, MO, USA). All experiments were repeated three times.

**Immunostaining of Frozen Sections** Mouse eyes were dissected; fixed in 4% paraformaldehyde at room temperature for 2h; dehydrated in 10%, 20%, and 30% sucrose; and embedded in optimal cutting temperature compound (O.C.T.) mounting medium. Frozen sections were cut using a cryostat

microtome apparatus and immunostained with anti-Tuj1 (1:500, Millipore, MAB1637), anti-RBPMS (1:500, Abcam, ab152101) and rabbit anti-Iba1 (1:300, Abcam, ab178847) antibodies. The nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). Slides were examined using an Axio Imager.M2 (Carl Zeiss, Germany). Cells positive for Iba1 and RBPMS were quantitatively analyzed using Image J software.

#### Quantitative Real-Time Polymerase Chain Reaction

Total RNA was extracted from mouse retinas using TRIzol Reagent. Following reverse transcription, reverse transcription polymerase chain reaction (RT-PCR) was performed using the following primers, manufactured by Sangon Biotech (Shanghai, China): tumor necrosis factor (TNF)- $\alpha$  (forward, 5'-ACGGCATGGATCTCAAAGAC-3', and reverse, 5'-AGATAGCAAATCGGCTGACG-3'); interleukin (IL)-1 $\beta$  (forward, 5'-GCAACGGGAAGATTCTGAAG-3', and reverse, 5'-TGACAACTTCTGCCTGACG-3'); inducible nitric oxide synthase (iNOS) (forward, 5'-ACGAGACGGATAGGCAGAGA-3', and reverse, 5'-CACATGCAAGGAAGGGAAG-3'); IL-4 forward, 5'-TCAACCCCGAGCTAGTTGTC-3', and reverse, 5'-TGTTCTTCGTTGCTGTGAGG-3').  $\beta$ -actin (forward, 5'-CACGATGGAGGGGCCGACTCATC-3', and reverse, 5'-TAAAGACCTCTATGCCAACACAGT-3').

#### Liquid Chromatography-Mass Spectroscopy and Untargeted Metabolomics Analyses

Two days after NMDA-induced injury, retinas were collected from the eicosane and control mouse groups ( $n=6$  each). The samples were homogenized in methanol by ultrasonication for 2min, placed in an ice-water bath for 10min, and centrifuged at 12000 $\times$ g for 10min at 4°C. The supernatants were collected, and metabolites were analyzed using a Dionex Ultimate 3000 RS UHPLC fitted with a Q-Exactive plus quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific) in both ESI-positive and ESI-negative ion modes. Compounds were identified based on their precise mass-to-charge ratios ( $M/z$ ) and isotopic distribution using The Human Metabolome (HMDB, <http://hmdb.ca>) and EMDB (<http://ebi.ac.uk/emdb/>) databases. Principle component analysis (PCA) was performed using a data matrix containing both the positive and negative ion data. Significant differences in metabolite concentrations between the two groups were determined using two-tailed Student's  $t$ -tests.

**Statistical Analysis** Data are presented as the mean percentage of control  $\pm$  standard error of mean (SEM) and compared by one-way analysis of variance with Tukey's multiple comparison tests. All statistical analyses were performed using GraphPad Prism 8, with statistical significance set at  $P<0.05$ .

## RESULTS

### Protective Effects of Eicosane on Glutamate-Induced R28 Cell Death

The protective effects of individual components


in *E. amoenum* L. ethanol extract on retinal neurons were assessed in R28 cells with glutamate-induced damage. The R28 retinal cell line, an adherent retinal precursor cell line derived from rat retina, is widely used for *in vitro* studies of retinal diseases. CCK-8 assays showed that tricosane and eicosane significantly augmented cell viability, with eicosane exhibiting the most pronounced protective effect (Figure 1A). Subsequent cell death assays showed that 10  $\mu$ mol/L eicosane notably attenuated glutamate-induced damage to R28 cells (Figure 1B, 1C), as well as significantly reducing glutamate-induced ROS production (Figure 1D). These findings collectively indicated that eicosane can protect retinal cells against glutamate-induced death, thereby providing empirical support for its neuroprotective efficacy.

### Neuroprotective and Anti-inflammatory Effects of Eicosane on NMDA-induced RGC Injury in a Mouse Glaucoma Model


To determine whether eicosane has a protective effect on NMDA-induced RGC injury in mice, mice were orally administered 20 mg/kg eicosane once daily for 10d, followed by intravitreal injection of NMDA. Immunofluorescence staining of retinal frozen sections showed that NMDA injection significantly reduced the number of RBPMS positive cells in the RGC layer, and that eicosane treatment effectively rescued NMDA-induced RGC loss (Figure 2A, 2B). TUNEL staining showed that eicosane treatment markedly attenuated NMDA-induced RGC cell death (Figure 2C, 2D). Microglial activation has been reported to damage RGCs in the retina, and inhibiting this activation may have a protective effect on RGCs in glaucoma. Iba1 immunofluorescence staining to detect microglia showed that the number of activated microglia was lower in the eicosane group than in the control group (Figure 3A, 3B). Moreover, the glutamate-induced elevation of mRNAs encoding proinflammatory cytokines such as TNF- $\alpha$ , iNOS and IL-1 $\beta$  was significantly decreased by eicosane treatment, whereas the glutamate-induced reduction of mRNA encoding the anti-inflammatory cytokine IL-4 was significantly increased upon eicosane treatment (Figure 3C). Taken together, these findings demonstrate that eicosane has neuroprotective and anti-inflammatory effects in this *in vivo* model of NMDA-induced glaucoma.

### Metabolomics Analyses of Metabolites and Pathways Involved in Responses to Eicosane Treatment


The effects of eicosane on metabolite changes in mouse retinas with NMDA-induced RGC damage were assessed by metabolomics analyses. Heat map clustering of the differentially expressed metabolites showed a distinctive metabolites expression pattern in NMDA after eicosane treatment when compared to NMDA treated group. Eicosane treatment was found to increase the levels of multiple metabolites in the retina, including L-arginine and L-carnitine (Figure 4A), with the



**Figure 1 Protective effects of eicosane on glutamate-induced R28 cell death** A: CCK-8 assays showing the effects of different components of *E. amoenum* ethanol extract on the viability of R28 cells treated with 10 mmol/L glutamate for 24h. B: Effects of 10  $\mu$ mol/L eicosane on the death of R28 cells treated with 10 mmol/L glutamate for 24h. C: Quantification of the percentage of dead cells. D: ROS production in glutamate-treated R28 cells, as determined by fluorescence-activated cell sorting. Scale bar=20  $\mu$ m. Data are mean $\pm$ SEM; <sup>a</sup>*P*<0.05, <sup>b</sup>*P*<0.01, <sup>c</sup>*P*<0.001. ROS: Reactive oxygen species; PI: Propidium iodide; SEM: Standard error of mean.



**Figure 2 Neuroprotective effects of eicosane on NMDA-induced RGC injury in a mouse glaucoma model** A: Retinas from different groups were harvested and frozen sections were immunostained with antibodies to RBPMS and Tuj1. B: Quantification of the number of RGCs in retinal sections. C: TUNEL staining of retinas from different groups. D: Quantification of the number of death cells in retinal sections. Scale bar=50  $\mu$ m. Data are mean $\pm$ SEM (*n*=6); <sup>a</sup>*P*<0.05, <sup>c</sup>*P*<0.001. RBPMS: RNA-binding protein with multiple splicing; Tuj1: Class III  $\beta$ -tubulin; TUNEL: (TdT) dUTP nick-end labeling. NMDA: N-methyl-D-aspartate; RGC: Retinal ganglion cell; SEM: Standard error of mean.



**Figure 3** Anti-inflammatory effects of eicosane on NMDA-induced RGC injury in a mouse glaucoma model. A: Retinas from different groups were harvested and immunostained with antibody to Iba1. B: Quantification of the number of microglia in retinal sections. Data are shown as the mean±SEM ( $n=6$ ). C: Relative levels of TNF- $\alpha$ , iNOS and IL-1 $\beta$  mRNAs, as determined by real-time PCR analysis. Scale bar=50  $\mu$ m. Data are shown as the mean±SEM ( $n=3$ ); <sup>a</sup> $P<0.05$ , <sup>b</sup> $P<0.01$ , <sup>c</sup> $P<0.001$  versus the control group. RGCs: Retinal ganglion cells; Iba1: Ionized calcium binding adaptor molecule 1; iNOS: Inducible nitric oxide synthase; NMDA: N-methyl-D-aspartate; SEM: Standard error of mean.

most changed metabolites shown in Figure 4B. The degree of linear correlation between pairs of metabolites was assessed by correlation analysis, with red indicating positive and blue indicating negative correlation. KEGG pathway analysis showed that pathways enriched by eicosane treatment included those associated with the process of autophagy, the mTOR pathway and the L-arginine metabolic pathway (Figure 4C). Highly positive correlations were observed between propionylcarnitine and L-carnitine, and between L-arginine and acetyl-L-carnitine (Figure 4D). These results indicated that these pathways may be putative downstream effectors induced by NMDA after eicosane treatment.


**Neuroprotective Effects of Eicosane may be due to its Modulation of Metabolites Production** Analysis of individual metabolites showed that eicosane treatment of mice with NMDA-induced RGC injury increased L-arginine, acetyl-L-carnitine, butanoyl-carnitine and L-carnitine contents, but reduced docosahexaenoic acid (DHA) content (Figure 5A). To determine whether eicosane-induced L-arginine and L-carnitine have protective effects on retinal neurons, L-arginine and L-carnitine were added individually to R28 cells with glutamate-induced damage. CCK-8 results showed that both

of these metabolites significantly increased cell viability (Figure 5B), and L-arginine and L-carnitine treatment also reduced glutamate-induced cell death (Figure 5C). Overall, these results suggest that eicosane may exert its neuroprotective effects by increasing the contents of these metabolites.

## DISCUSSION

Eicosane is a naturally occurring hydrocarbon compound found in several plants, including *Drosera indica* L. and *Barringtonia asiatica* L.<sup>[8-9]</sup>. Eicosane exhibits notable anti-inflammatory and antimicrobial properties<sup>[10]</sup>. For example, in a diabetic rat wound model, the administration of eicosane and octadecane accelerated wound healing. Both compounds were found to possess robust free radical scavenging activity and interacted with matrix metalloproteinases (MMPs)<sup>[11]</sup>. Eicosane functions as a ligand, binding to the taste receptor BminGR59b of *Bactrocera minax*, a significant citrus pest. This interaction mediates precise host plant selection for oviposition through the insect's taste system<sup>[12]</sup>. A study utilizing thermal desorption-gas chromatography-mass spectrometry to analyze sebum volatiles collected from Parkinson's patients and healthy individuals identified a cluster of volatile metabolites associated with Parkinson's disease,





**Figure 5** Eicosane-associated neuroprotection may be due to its modulation of metabolite production A: Effects of eicosane on L-arginine, acetyl-L-carnitine, butanoyl-carnitine, L-carnitine, and docosahexaenoic acid (DHA) contents on NMDA-induced RGC injury in a mouse model of glaucoma; B: Effects of L-arginine and L-carnitine on the viability of R28 cells treated with 10 mmol/L glutamate for 24h, as determined by CCK-8 assays; C: Effects of L-arginine and L-carnitine on cell death of R28 cells treated with 10 mmol/L glutamate for 24h, as determined by PI staining. Data are mean±SEM; <sup>a</sup>*P*<0.05, <sup>b</sup>*P*<0.01, <sup>c</sup>*P*<0.001. PI: Propidium iodide; NMDA: N-methyl-D-aspartate; RGCs: Retinal ganglion cells; SEM: Standard error of the mean.

mice with NMDA-induced RGC injury glaucoma mice, and that the levels of these metabolites were increased by eicosane treatment. Furthermore, L-arginine or L-carnitine treatment was found to significantly increase the viability of R28 cells with glutamate-induced damage. Taken together, these findings suggest that the neuroprotective activity of eicosane may be due to its mediation of L-arginine or L-carnitine metabolism. Additional studies, however, are needed to better understand the roles of arginine and carnitine metabolism in retinal diseases and to develop potential therapeutic strategies to modulate these metabolic pathways in the treatment of glaucoma.

**ACKNOWLEDGEMENTS**

**Foundation:** Supported by the Science and Technology Innovation Program of Hunan Province (No.2018SK50208).

**Conflicts of Interest:** Wu ZK, None; Li HY, None; Zhu YL, None; Xiong MQ, None; Zhong JX, None.

**REFERENCES**

1 Lakshmanan Y, Wong FSY, So KF, Chan HH. Potential role of *Lycium barbarum* polysaccharides in glaucoma management: evidence from preclinical *in vivo* studies. *Neural Regen Res* 2023;18(12):2623-2632.  
 2 Sim RH, Sirasanagandla SR, Das S, Teoh SL. Treatment of glaucoma with natural products and their mechanism of action: an update.

*Nutrients* 2022;14(3):534.  
 3 Maekawa S, Sato K, Kokubun T, Himori N, Yabana T, Ohno-Oishi M, Shi G, Omodaka K, Nakazawa T. A plant-derived antioxidant supplement prevents the loss of retinal ganglion cells in the retinas of NMDA-injured mice. *Clin Ophthalmol* 2022;16:823-832.  
 4 Akbari B, Baghaei-Yazdi N, Bahmaie M, Mahdavi Abhari F. The role of plant-derived natural antioxidants in reduction of oxidative stress. *Biofactors* 2022;48(3):611-633.  
 5 Mahdipour R, Ebrahimzadeh-Bideskan A, Hosseini M, Shahba S, Lombardi G, Malvandi AM, Mohammadipour A. The benefits of grape seed extract in neurological disorders and brain aging. *Nutr Neurosci* 2023;26(5):369-383.  
 6 Rahul, Siddique YH. Neurodegenerative diseases and flavonoids: special reference to kaempferol. *CNS Neurol Disord Drug Targets* 2021;20(4):327-342.  
 7 Li HB, Behnammanesh G, Wu ZK, Rong R, You ML, Majid ASA, Ji D. *Echium amoenum* L. ethanol extract protects retinal ganglion cell after glutamate and optic nerve crush injury. *Dis Markers* 2022;2022:3631532.  
 8 Umaru IJ, Badruddin FA, Umaru HA. Phytochemical screening of essential oils and antibacterial activity and antioxidant properties of *Barringtonia asiatica* (L) leaf extract. *Biochem Res Int* 2019;2019: 7143989.

- 9 Gomathi D, Kalaiselvi M, Ravikumar G, Devaki K, Uma C. GC-MS analysis of bioactive compounds from the whole plant ethanolic extract of *Evolvulus alsinoides* (L.) L. *J Food Sci Technol* 2015;52(2):1212-1217.
- 10 Beema Shafreen RM, Seema S, Alagu Lakshmi S, Srivathsan A, Tamilmuhilan K, Shrestha A, Balasubramanian B, Dhandapani R, Paramasivam R, Al Obaid S, Salmen SH, Mohd Amin MF, Muthupandian S. *In vitro* and *in vivo* antibiofilm potential of eicosane against *Candida albicans*. *Appl Biochem Biotechnol* 2022;194(10):4800-4816.
- 11 Balachandran A, Choi SB, Beata MM, Małgorzata J, Froemming GRA, Lavilla CA Jr, Billacura MP, Siyumbwa SN, Okechukwu PN. Antioxidant, wound healing potential and *in silico* assessment of naringin, eicosane and octacosane. *Molecules* 2023;28(3):1043.
- 12 Zhang GJ, Cao S, Wang HR, Cao Z, Wei BB, Niu CY. Identification of a new gustatory receptor *BminGR59b* tuned to host wax in a specialist, *Bactrocera minax* (Diptera: Tephritidae). *Int J Biol Macromol* 2023;253:127180.
- 13 Trivedi DK, Sinclair E, Xu Y, Sarkar D, Walton-Doyle C, Liscio C, Banks P, Milne J, Silverdale M, Kunath T, Goodacre R, Barran P. Discovery of volatile biomarkers of Parkinson's disease from sebum. *ACS Cent Sci* 2019;5(4):599-606.
- 14 Zhang ZQ, Xie Z, Chen SY, Zhang X. Mitochondrial dysfunction in glaucomatous degeneration. *Int J Ophthalmol* 2023;16(5):811-823.
- 15 Gasiunas K, Galgauskas S. Green tea-a new perspective of glaucoma prevention. *Int J Ophthalmol* 2022;15(5):747-752.
- 16 Ruan Y, Jiang SB, Musayeva A, Gericke A. Oxidative stress and vascular dysfunction in the retina: therapeutic strategies. *Antioxidants* 2020;9(8):761.
- 17 Leruez S, Marill A, Bresson T, de Saint Martin G, Buisset A, Muller J, Tessier L, Gadras C, Verny C, Gohier P, Amati-Bonneau P, Lenaers G, Bonneau D, Simard G, Milea D, Procaccio V, Reynier P, Chao de la Barca JM. A metabolomics profiling of glaucoma points to mitochondrial dysfunction, senescence, and polyamines deficiency. *Invest Ophthalmol Vis Sci* 2018;59(11):4355-4361.
- 18 Kouassi Nzoughet J, Guehlouz K, Leruez S, Gohier P, Bocca C, Muller J, Blanchet O, Bonneau D, Simard G, Milea D, Procaccio V, Lenaers G, Chao de la Barca JM, Reynier P. A data mining metabolomics exploration of glaucoma. *Metabolites* 2020;10(2):E49.
- 19 Lillo A, Marin S, Serrano-Marin J, Binetti N, Navarro G, Cascante M, Sánchez-Navés J, Franco R. Targeted metabolomics shows that the level of glutamine, kynurenine, acyl-carnitines and lysophosphatidylcholines is significantly increased in the aqueous humor of glaucoma patients. *Front Med* 2022;9:935084.
- 20 Sato K, Saigusa D, Kokubun T, Fujioka A, Feng QW, Saito R, Uruno A, Matsukawa N, Ohno-Oishi M, Kunikata H, Yokoyama Y, Yasuda M, Himori N, Omodaka K, Tsuda S, Maekawa S, Yamamoto M, Nakazawa T. Reduced glutathione level in the aqueous humor of patients with primary open-angle glaucoma and normal-tension glaucoma. *NPJ Aging* 2023;9(1):28.